All > Mci > Mild Cognitive Impairment

Dexmedetomidine Hydrochloride Group for Cognitive Impairment

Phase-Based Progress Estimates
3
Effectiveness
3
Safety
Cognitive Impairment+16 MoreDexmedetomidine Hydrochloride Group - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing whether the drug Dexmedetomidine can prevent postoperative cognitive dysfunction (POCD), which is when patients have trouble thinking and remembering after surgery.

Eligible Conditions
  • Cognitive Impairment
  • Hypnotics and Sedatives
  • Dexmedetomidine
  • Central Nervous System Depressants
  • Neurobehavioral Symptoms
  • Confusion
  • Delirium
  • Nervous System Disorders
  • Neurocognitive Disorder
  • Mental Illness
  • Symptoms
  • Painkillers
  • Cognitive Disorders
  • Neurologic Symptoms
  • Drug Effects
  • Molecular Pharmacology
  • Non-Narcotic Analgesics

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Similar Trials

1
Memantine
1
CYNK-001
1
Dexmedetomidine subcutaneous continuous infusion

Study Objectives

1 Primary · 10 Secondary · Reporting Duration: 3, 6, 12 months

Month 12
Post-operative cognitive dysfunction (POCD) at 1 week, 6 months, 12 months after surgery
3 months
Post-operative cognitive dysfunction
3, 6, 12 months
Quality of Surgical Recovery
Month 12
Depressive symptoms
Mild Cognitive Impairment
Persistent Surgical Site Pain
4 days
Opioid consumption to POD 4
Day 14
Length of stay
Day 10
Delirium
Hour 12
Time to extubation
Week 1
In-hospital mortality for index surgery

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Similar Trials

1
Memantine
1
CYNK-001
1
Dexmedetomidine subcutaneous continuous infusion

Trial Design

2 Treatment Groups

Standard of Care Group
1 of 2
Dexmedetomidine Hydrochloride Group
1 of 2

Active Control

2400 Total Participants · 2 Treatment Groups

Primary Treatment: Dexmedetomidine Hydrochloride Group · No Placebo Group · Phase 4

Standard of Care GroupNoIntervention Group · 1 Intervention: Standard of Care Group · Intervention Types:
Dexmedetomidine Hydrochloride Group
Drug
ActiveComparator Group · 1 Intervention: Dexmedetomidine Hydrochloride Group · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 3, 6, 12 months

Who is running the clinical trial?

Sunnybrook Health Sciences CentreLead Sponsor
604 Previous Clinical Trials
1,466,787 Total Patients Enrolled
London Health Sciences CentreOTHER
136 Previous Clinical Trials
45,281 Total Patients Enrolled
McMaster UniversityOTHER
801 Previous Clinical Trials
1,725,477 Total Patients Enrolled
University Health Network, TorontoOTHER
1,380 Previous Clinical Trials
471,039 Total Patients Enrolled
Stephen Choi, MD,MSc,FRCPCPrincipal InvestigatorSunnybrook Health Sciences Centre
1 Previous Clinical Trials
90 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top